AOD-9604 · Research brief

AOD-9604 vs LIPO-C — Mechanism, Efficacy, Clinical Use

Real Peptides Research TeamEditorial

Updated April 9, 20269 min read

53 WORDS

Short answer

Key takeaways

AOD-9604 is a 15-amino-acid synthetic peptide derived from the C-terminal fragment of human growth hormone, designed to stimulate lipolysis without activating IGF-1 or affecting glucose metabolism.
LIPO-C is a lipotropic injection combining methionine, inositol, choline, and cyanocobalamin. Nutrients that support hepatic methylation and fat transport rather than direct fat cell signalling.
AOD-9604 binds to beta-3 adrenergic receptors on adipocytes and activates hormone-sensitive lipase, mobilising stored triglycerides into free fatty acids that must then be oxidised through energy expenditure.
LIPO-C provides methyl donors and cofactors required for phosphatidylcholine synthesis, enabling the liver to package triglycerides into VLDL particles and export them from hepatocytes.
Clinical evidence for AOD-9604 includes one Phase IIa trial showing modest fat loss vs placebo, but subsequent Phase IIb development was discontinued after failing primary endpoints.
LIPO-C has no published randomised controlled trials demonstrating efficacy. Its use is supported by mechanistic rationale and observational clinical experience in integrative medicine contexts.
The difference between AOD-9604 and LIPO-C is not one of potency but of physiological target. AOD-9604 acts on fat cells; LIPO-C acts on liver function.

Researchers at Monash University isolated the C-terminal fragment of human growth hormone (hGH) and found that amino acids 177–191 retained the fat-mobilising properties of the full molecule without triggering insulin resistance or IGF-1 elevation. That fragment became AOD-9604. LIPO-C, by contrast, is a lipotropic injection combining methionine, inositol, choline, and cyanocobalamin (vitamin B12). Compounds that support hepatic methylation pathways and phospholipid synthesis rather than direct lipolytic signalling. The mechanisms don't overlap. One acts on adipocyte surface receptors to stimulate intracellular lipase; the other provides methyl donors that enable the liver to package and export triglycerides.

Our team has worked with researchers evaluating both compounds across varied metabolic contexts. The confusion between AOD-9604 and LIPO-C stems from their shared use in weight management protocols. But the biological pathways they influence are fundamentally distinct.

What's the difference between AOD-9604 and LIPO-C?

AOD-9604 is a 15-amino-acid synthetic peptide (tyrosine-hGH fragment 177–191) that binds to beta-3 adrenergic receptors on adipocytes, stimulating hormone-sensitive lipase to break down stored triglycerides into free fatty acids. LIPO-C is a compound injection containing methionine, inositol, choline, and cyanocobalamin. Lipotropic agents that support hepatic fat metabolism by donating methyl groups required for phosphatidylcholine synthesis and VLDL assembly. AOD-9604 acts on fat cells directly; LIPO-C acts on liver function indirectly.

The distinction matters because outcome expectations differ. AOD-9604 is investigated primarily for localised fat reduction and cartilage repair in preclinical models. Its lipolytic effect is receptor-mediated. LIPO-C supports generalised hepatic fat clearance and is used adjunctively in metabolic protocols where bile flow, methylation capacity, or B-vitamin status may be suboptimal. This article covers the structural composition of both compounds, their respective mechanisms of action, clinical evidence (or lack thereof) supporting efficacy claims, dosing protocols used in research settings, and scenarios where one might be prioritised over the other.

Structural Composition and Biological Origin

AOD-9604 is a synthetically modified peptide comprising amino acids 177–191 of the C-terminal region of human growth hormone, with a tyrosine residue added at the N-terminus to stabilise the molecule and enhance receptor binding affinity. The fragment was isolated after researchers identified that hGH's lipolytic activity. Its ability to stimulate fat breakdown. Resides in this specific 15-amino-acid sequence rather than in the full 191-amino-acid protein. By isolating this fragment, AOD-9604 retains the fat-mobilising properties of growth hormone without activating IGF-1 (insulin-like growth factor 1) or interfering with glucose metabolism. Effects associated with full-length hGH that make it unsuitable for non-endocrine therapeutic use.

LIPO-C is not a single molecule but a formulation combining four distinct compounds: L-methionine (an essential amino acid and methyl donor), myo-inositol (a carbocyclic sugar alcohol involved in cellular signalling), choline (a precursor to phosphatidylcholine and acetylcholine), and cyanocobalamin (vitamin B12, required as a cofactor in methylation reactions). These components are lipotropic agents. Substances that promote the mobilisation and metabolism of fat within the liver. Methionine provides methyl groups used in the synthesis of S-adenosylmethionine (SAMe), the universal methyl donor in human biochemistry. Choline is required for phosphatidylcholine production, the predominant phospholipid in VLDL particles that transport triglycerides out of the liver. Inositol supports insulin signalling and lipid membrane integrity. B12 serves as a cofactor in homocysteine remethylation, indirectly supporting methylation capacity.

The structural difference is categorical: AOD-9604 is a receptor agonist peptide; LIPO-C is a nutrient cofactor blend. This distinction determines how each compound interacts with physiological systems and what outcomes are plausible.

Mechanism of Action — Receptor Signalling vs Metabolic Support

AOD-9604 exerts its lipolytic effect by binding to beta-3 adrenergic receptors on the surface of adipocytes. The same receptors activated by catecholamines like norepinephrine during fasted or exercise states. Once bound, AOD-9604 triggers a cAMP-mediated signalling cascade that activates hormone-sensitive lipase (HSL), the enzyme responsible for hydrolysing triglycerides stored within fat cells into free fatty acids and glycerol. These liberated fatty acids are then released into the bloodstream, where they can be oxidised by muscle tissue or other metabolically active organs. Critically, AOD-9604 does not directly oxidise fat. It mobilises it. Without concurrent energy demand (caloric deficit, exercise, or thermogenic activity), the freed fatty acids are simply re-esterified and stored again.

LIPO-C operates through an entirely different pathway. Methionine and choline donate methyl groups and precursors required for hepatic phosphatidylcholine synthesis. The phospholipid that forms the outer shell of very-low-density lipoprotein (VLDL) particles. When the liver accumulates triglycerides (from dietary fat, de novo lipogenesis, or adipose tissue lipolysis), it must package those triglycerides into VLDL particles to export them into circulation. Without adequate phosphatidylcholine, triglycerides remain trapped in hepatocytes, leading to hepatic steatosis (fatty liver). Choline deficiency is a well-documented cause of non-alcoholic fatty liver disease in animal models. Inositol enhances insulin receptor sensitivity and supports second-messenger signalling pathways involved in glucose and lipid metabolism. B12, as a cofactor in methionine synthase, ensures that homocysteine is efficiently converted back to methionine, preserving methylation capacity across the body.

In our experience working with researchers evaluating lipotropic formulations, LIPO-C does not 'burn fat'. It facilitates the liver's ability to process and export fat that has already been mobilised or synthesised. If hepatic methylation pathways are saturated or B-vitamin cofactors are depleted, fat clearance slows regardless of lipolytic signalling upstream. AOD-9604 and LIPO-C are not redundant. They address different bottlenecks in fat metabolism.

AOD-9604 vs LIPO-C: Evidence and Clinical Efficacy Comparison

Factor	AOD-9604	LIPO-C	Bottom Line
Primary Mechanism	Beta-3 adrenergic receptor agonist. Stimulates hormone-sensitive lipase in adipocytes to release free fatty acids	Lipotropic nutrient blend. Provides methyl donors and cofactors required for hepatic phosphatidylcholine synthesis and VLDL assembly	AOD-9604 is receptor-mediated lipolysis; LIPO-C is hepatic metabolic support
Clinical Trial Evidence	Phase IIa human trial (2004) showed statistically significant fat loss vs placebo over 12 weeks; Phase IIb trial failed primary endpoint and development halted	No peer-reviewed RCTs exist; evidence limited to observational case series and anecdotal clinical use in integrative medicine settings	AOD-9604 has modest human trial data; LIPO-C has none
Approved Regulatory Status	Not FDA-approved; available as a research peptide through compounding facilities and peptide suppliers	Not FDA-approved as a standalone therapeutic; individual components (methionine, choline, inositol, B12) are dietary nutrients
Typical Research Dosage	300 mcg subcutaneously once daily, typically administered in fasted state or pre-exercise	1–2 mL intramuscularly 1–3 times per week; exact dosing varies by formulation and clinical protocol	AOD-9604 is dosed daily; LIPO-C is dosed intermittently
Expected Onset of Effect	2–4 weeks for measurable change in body composition when combined with caloric deficit and exercise	Effects are indirect and cumulative. Improved liver enzyme markers and subjective energy within 2–4 weeks if deficiency is present	Neither produces rapid weight loss; both require structured metabolic context
Side Effect Profile	Generally well-tolerated; mild injection site reactions, transient headache, and gastrointestinal discomfort reported in trials	Minimal; nausea if injected too rapidly, rare allergic reaction to cyanocobalamin	Both are low-risk in short-term research use

What If: AOD-9604 and LIPO-C Scenarios

What If I Use AOD-9604 Without a Caloric Deficit?

AOD-9604 mobilises fat from adipocytes by stimulating hormone-sensitive lipase, but mobilisation is not the same as oxidation. If you release free fatty acids into the bloodstream without concurrent energy demand. From caloric restriction, exercise, or thermogenic activity. Those fatty acids are simply taken back up by adipocytes and re-esterified into triglycerides. Research protocols that demonstrated fat loss with AOD-9604 combined the peptide with controlled caloric intake and regular physical activity. The peptide does not override energy balance. It facilitates fat mobilisation within a context where that mobilised fat will actually be used.

What If I Take LIPO-C But My Methylation Pathways Are Already Sufficient?

LIPO-C is most beneficial when hepatic methylation capacity is rate-limiting. Meaning the liver cannot produce enough phosphatidylcholine to efficiently export triglycerides. If your diet already provides adequate choline, methionine, and B-vitamins, and your liver is functioning optimally, additional lipotropic supplementation will have minimal impact. LIPO-C is not a fat burner. It removes a bottleneck. If that bottleneck does not exist, the formulation provides little incremental benefit beyond baseline nutritional status.

What If I Combine AOD-9604 and LIPO-C in the Same Protocol?

Combining AOD-9604 and LIPO-C addresses two different stages of fat metabolism: mobilisation and hepatic clearance. AOD-9604 releases fat from adipocytes; LIPO-C ensures the liver can process and export that fat once it arrives. This combination is sometimes used in integrative metabolic protocols, but no peer-reviewed trials have evaluated the synergistic efficacy of the two together. The theoretical rationale is sound. Enhanced lipolysis paired with enhanced hepatic lipid export. But the practical outcome still depends on energy balance, insulin sensitivity, and overall metabolic context.

The Honest Truth About AOD-9604 and LIPO-C

Here's the honest answer: neither AOD-9604 nor LIPO-C is a standalone fat loss solution. AOD-9604 has modest clinical evidence showing it can support fat loss when combined with caloric deficit and exercise. But it does not override thermodynamics. LIPO-C has no published clinical trials demonstrating efficacy at all; its use is based on mechanistic rationale and anecdotal clinical experience. Both compounds are tools that address specific physiological bottlenecks. AOD-9604 for fat mobilisation, LIPO-C for hepatic fat clearance. But neither replaces the fundamental metabolic levers of diet, activity, and insulin sensitivity. The marketing around both compounds often overstates their independent effects. The difference between AOD-9604 and LIPO-C is not a matter of which is 'better'. It's a matter of which bottleneck you're addressing and whether that bottleneck is rate-limiting in your specific metabolic context.

Dosing Protocols and Administration Considerations

AOD-9604 is typically administered as a subcutaneous injection at doses ranging from 250–500 mcg per day, with the most common research protocol using 300 mcg once daily. Timing of administration varies: some protocols recommend dosing in a fasted state (upon waking or before fasted cardio) to maximise lipolytic signalling when endogenous insulin is low and catecholamines are elevated. Others dose pre-exercise to align peak peptide activity with energy expenditure. The peptide is supplied as a lyophilised powder that must be reconstituted with bacteriostatic water and stored at 2–8°C after reconstitution. Once mixed, AOD-9604 retains stability for approximately 28 days under refrigeration.

LIPO-C is administered intramuscularly at doses of 1–2 mL per injection, typically 1–3 times per week depending on clinical protocol and individual response. The formulation is pre-mixed and does not require reconstitution. Injection sites include the deltoid, vastus lateralis, or gluteal muscle. Unlike AOD-9604, LIPO-C is not time-sensitive. It provides cofactors that accumulate and support ongoing hepatic function rather than triggering acute receptor signalling. Some integrative medicine practitioners recommend LIPO-C injections on days when caloric intake is higher or when alcohol is consumed, under the rationale that hepatic methylation demand is elevated in these contexts.

Our team has observed that injection site reactions are more common with LIPO-C than with AOD-9604, likely due to the higher injection volume and intramuscular route. Both compounds are generally well-tolerated when prepared under sterile conditions and administered correctly. Neither is FDA-approved, and both are used in research or off-label clinical contexts. Typically through integrative medicine clinics, compounding pharmacies, or peptide research suppliers like Real Peptides.

At Real Peptides, every peptide is synthesised through small-batch production with exact amino-acid sequencing, ensuring the structural integrity that makes compounds like AOD-9604 functionally viable. Purity and consistency are non-negotiable when working with receptor-targeted peptides. A single amino acid substitution or degradation can eliminate biological activity entirely. You can explore high-purity research peptides designed for rigorous lab standards.

If fat mobilisation is your primary target and you're working within a structured caloric deficit, AOD-9604 addresses that bottleneck directly. If hepatic fat clearance or methylation capacity is the limiting factor. Particularly in contexts of high alcohol intake, choline-deficient diets, or pre-existing fatty liver. LIPO-C provides the cofactors your liver needs to function optimally. The difference between AOD-9604 and LIPO-C is the difference between signalling fat cells to release and enabling the liver to process what's been released.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

AOD-9604 is a 15-amino-acid fragment of human growth hormone’s C-terminal region that retains the lipolytic (fat-mobilising) domain but lacks the N-terminal sequences responsible for IGF-1 activation and insulin antagonism. By isolating amino acids 177–191, researchers at Monash University preserved the peptide’s ability to bind beta-3 adrenergic receptors on adipocytes and stimulate hormone-sensitive lipase without triggering the glucose metabolism disruptions associated with full-length hGH. This makes AOD-9604 functionally selective for lipolysis.

LIPO-C injections bypass first-pass hepatic metabolism and deliver methionine, choline, inositol, and cyanocobalamin directly into circulation at concentrations higher than oral supplementation typically achieves. If you’re already taking oral lipotropic supplements and your liver function markers (ALT, AST) and methylation status (homocysteine levels) are optimal, additional LIPO-C injections may provide minimal incremental benefit. However, in cases of impaired absorption or high metabolic demand, intramuscular delivery can be more effective than oral dosing.

AOD-9604 acts on adipocytes (fat cells) by binding to beta-3 adrenergic receptors on the cell surface and stimulating intracellular lipase enzymes that break down stored triglycerides. LIPO-C acts on hepatocytes (liver cells) by providing methyl donors and cofactors required for phosphatidylcholine synthesis, which enables the liver to package triglycerides into VLDL particles and export them into circulation. The difference is anatomical and mechanistic — one targets fat cells, the other targets liver function.

AOD-9604 research protocols typically show measurable changes in body composition within 4–8 weeks when combined with caloric deficit and exercise — the peptide mobilises fat, but fat loss still depends on energy balance. LIPO-C does not directly cause fat loss; it supports hepatic fat clearance and methylation capacity. Subjective improvements (energy, mental clarity, liver enzyme normalisation) may appear within 2–4 weeks if underlying choline or B-vitamin deficiency is present, but body composition changes with LIPO-C alone are indirect and require longer observation.

AOD-9604 has been studied in human trials for up to 12 weeks with no serious adverse events reported, but long-term safety data beyond that timeframe does not exist in peer-reviewed literature. Most research protocols use AOD-9604 in 8–12 week cycles rather than continuous administration. The peptide is not FDA-approved, and its long-term metabolic effects — particularly on beta-3 receptor sensitivity and endogenous lipolytic signalling — have not been characterised in extended-use studies.

LIPO-C’s primary mechanism — providing choline and methionine for phosphatidylcholine synthesis — directly addresses one cause of hepatic steatosis (fatty liver): impaired VLDL assembly due to choline deficiency. Animal models demonstrate that choline-deficient diets reliably induce fatty liver, and supplementation reverses it. However, non-alcoholic fatty liver disease in humans is multifactorial, involving insulin resistance, oxidative stress, and inflammatory pathways. LIPO-C may support hepatic fat export, but it is not a standalone treatment for NAFLD and should be part of a broader metabolic intervention.

There is no known pharmacological interaction between AOD-9604 and LIPO-C — they act on different tissues through different mechanisms. AOD-9604 stimulates fat mobilisation from adipocytes; LIPO-C supports hepatic fat clearance. Some integrative medicine protocols combine both under the rationale that enhanced lipolysis paired with enhanced hepatic lipid export may produce additive benefit, but no published trials have evaluated this combination directly. Both can be administered concurrently without biochemical conflict.

AOD-9604 does not alter baseline metabolic rate or adipocyte number — it temporarily enhances lipolytic signalling while active. Once discontinued, fat mobilisation returns to baseline levels determined by diet, exercise, and endogenous catecholamine activity. If you maintained fat loss during AOD-9604 use through caloric deficit and increased the deficit or activity to compensate for the peptide’s absence, fat regain is not inevitable. However, if AOD-9604 was the primary driver of fat mobilisation and energy balance shifts back to maintenance or surplus, regain is likely.

AOD-9604’s Phase IIa trial (2004) demonstrated statistically significant fat loss vs placebo, but the Phase IIb trial failed to meet its primary endpoint, likely due to issues with dosing, trial design, or subject heterogeneity rather than a complete lack of biological activity. The peptide’s developer, Metabolic Pharmaceuticals, discontinued further development after the Phase IIb failure, and AOD-9604 never advanced to Phase III or FDA approval. The compound remains available as a research peptide, but it lacks the clinical validation required for mainstream therapeutic use.

If your diet provides 400–550 mg of choline daily (the adequate intake level for adults) and your liver function is optimal, additional LIPO-C injections are unlikely to produce meaningful benefit. Lipotropic supplementation is most effective when dietary intake is insufficient or when metabolic demand exceeds supply — such as in cases of high alcohol consumption, pregnancy, or pre-existing hepatic steatosis. LIPO-C does not enhance fat metabolism beyond the point where methylation pathways are no longer rate-limiting.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA